PMID- 24225639
OWN - NLM
STAT- MEDLINE
DCOM- 20140808
LR  - 20141120
IS  - 1476-5462 (Electronic)
IS  - 0969-7128 (Linking)
VI  - 21
IP  - 1
DP  - 2014 Jan
TI  - Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced 
      with modified adenoviral vector containing type 35 fiber structures.
PG  - 106-14
LID - 10.1038/gt.2013.65 [doi]
AB  - For successful clinical tumor immunotherapy outcomes, strong immune responses 
      against tumor antigens must be generated. Cell-based vaccines compromise one 
      strategy with which to induce appropriate strong immune responses. Previously, we 
      established a natural killer T-cell (NKT) ligand-loaded, adenoviral 
      vector-transduced B-cell-based anticancer cellular vaccine. To enhance tumor 
      antigen delivery to B cells, we established a modified adenoviral vector (Ad-k35) 
      that encoded a truncated form of the breast cancer antigen Her2/neu (Ad-k35HM) in 
      which fiber structure was substituted with adenovirus serotype 35. We observed 
      increased tumor antigen expression with Ad-k35HM in both human and murine B 
      cells. In addition, an Ad-k35HM-transduced B-cell vaccine elicited strong 
      antigen-specific cellular and humoral immune responses that were further enhanced 
      with the additional loading of soluble NKT ligand KBC009. An Ad-k35HM-transduced, 
      KBC009-loaded B-cell vaccine efficiently suppressed the in vivo growth of 
      established tumors in a mouse model. Moreover, the vaccine elicited human 
      leukocyte antigen (HLA)-A2 epitope-specific cytotoxic T-cell responses in B6.Cg 
      (CB)-Tg (HLA-A/H2-D) 2Enge/Jat mice. These findings indicated that the Ad-k35 
      could be appropriate for the preclinical and clinical development of B-cell-based 
      anticancer immunotherapies.
FAU - Kim, E-K
AU  - Kim EK
AD  - Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, College 
      of Pharmacy, Seoul National University, Seoul, Korea.
FAU - Seo, H-S
AU  - Seo HS
AD  - WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate 
      School of Convergence Science and Technology, Seoul National University, Seoul, 
      Korea.
FAU - Chae, M-J
AU  - Chae MJ
AD  - Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, College 
      of Pharmacy, Seoul National University, Seoul, Korea.
FAU - Jeon, I-S
AU  - Jeon IS
AD  - WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate 
      School of Convergence Science and Technology, Seoul National University, Seoul, 
      Korea.
FAU - Song, B-Y
AU  - Song BY
AD  - WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate 
      School of Convergence Science and Technology, Seoul National University, Seoul, 
      Korea.
FAU - Park, Y-J
AU  - Park YJ
AD  - Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, College 
      of Pharmacy, Seoul National University, Seoul, Korea.
FAU - Ahn, H M
AU  - Ahn HM
AD  - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, 
      Korea.
FAU - Yun, C-O
AU  - Yun CO
AD  - Department of Bioengineering, College of Engineering, Hanyang University, Seoul, 
      Korea.
FAU - Kang, C-Y
AU  - Kang CY
AD  - 1] Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, 
      College of Pharmacy, Seoul National University, Seoul, Korea [2] WCU Department 
      of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of 
      Convergence Science and Technology, Seoul National University, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131114
PL  - England
TA  - Gene Ther
JT  - Gene therapy
JID - 9421525
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - B-Lymphocytes/*immunology/virology
MH  - *Cancer Vaccines/immunology
MH  - Cells, Cultured
MH  - Dependovirus/*genetics/metabolism
MH  - Female
MH  - Genetic Vectors
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Immunotherapy
MH  - Mammary Neoplasms, Experimental/immunology/*therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Natural Killer T-Cells/immunology
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2013/11/15 06:00
MHDA- 2014/08/13 06:00
CRDT- 2013/11/15 06:00
PHST- 2013/05/15 00:00 [received]
PHST- 2013/06/14 00:00 [revised]
PHST- 2013/09/23 00:00 [accepted]
PHST- 2013/11/15 06:00 [entrez]
PHST- 2013/11/15 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - gt201365 [pii]
AID - 10.1038/gt.2013.65 [doi]
PST - ppublish
SO  - Gene Ther. 2014 Jan;21(1):106-14. doi: 10.1038/gt.2013.65. Epub 2013 Nov 14.